Detailed tracking of antigen and antibody levels during coronavirus disease 2019 treatment in an immunosuppressed patient with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
J Infect Chemother
; 30(9): 922-927, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38342142
ABSTRACT
A 67-year-old woman with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis was not vaccinated against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was on multiple immunosuppressive drugs. She was hospitalized because of interstitial shadowing in the lungs and diagnosed with persistent coronavirus disease 2019 (COVID-19). Despite treatment with a recombinant monoclonal antibody and antivirals, her symptoms persisted and she lacked a specific antibody response. She tested negative for SARS-CoV-2 antigen after the second antiviral treatment, and a subsequent chest radiograph showed improvement. However, the antibody levels did not change. This case highlights the importance of careful monitoring of the SARS-CoV-2 antigen and antibody levels during COVID-19 treatment in patients with immunosuppression.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Hospedeiro Imunocomprometido
/
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos
/
SARS-CoV-2
/
COVID-19
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article